Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company focused on antibody engineering and discovery, leveraging its proprietary DiversImmune platform to develop differentiated therapeutic candidates across oncology and immunology. The company became publicly traded through its business combination with Chavant Capital Acquisition Corp., a blank-check company that completed its IPO in 2021, with Chavant Capital Partners serving as sponsor. The combined entity began trading under the ABP ticker following the de-SPAC transaction close, transitioning Abpro's antibody technology programs into the public markets. The September 2026 Form 8-K filing reflects continued post-merger reporting obligations. Visit SpacDesk to access the full filing history, deal terms, and real-time data on ABP and hundreds of other SPAC transactions.